

Leukaemia Section

Short Communication

t(11;19)(q23;p13) KMT2A/MYO1F

Jean-Loup Huret

jean-loup.huret@atlasgeneticsoncology.org

Published in Atlas Database: April 2018

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/t1119q23p13ID1406.html>

Printable original version : <http://documents.irevues.inist.fr/bitstream/handle/2042/68972/04-2018-t1119q23p13ID1406.pdf>

DOI: 10.4267/2042/68972

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.

© 2018 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

Review on t(11;19)(q23;p13), with data on clinics, and the genes involved.

KEYWORDS

Chromosome 11; Chromosome 19; KMT2A; MYO1F; Acute myeloid leukemia

Clinics and pathology

Disease

Acute myeloid leukemia

Phenotype/cell stem origin

Seven cases are available, six of them were infant patients. Two were diagnosed with acute monocytic leukemia (AMoL) (Taki et al., 2005; Duhoux et al., 2011). There were also 4 other cases of infant AML, not otherwise specified (NOS) (Lo Nigro et al., 2002; Meyer et al. 2013) and 1 pediatric AML-NOS (Meyer et al. 2013).

Epidemiology

In the large study by Meyer et al., 2013, the four cases (3 infant AML, 1 pediatric AML) were part of a series of 692 infant ALL, 160 infant AMLs, 339 pediatric AMLs, 313 pediatric ALLs, 415 adult ALLs and 373 adult AMLs. This chromosome abnormality seems so far restricted to a subset of patients: extremely young patients with a diagnosis of AML.

Clinics

One patient was diagnosed at birth (Duhoux et al., 2011), and another one at 2 months of age (Taki et al., 2005).

Prognosis

Scarce data: one patient died 5 days after admission (Taki et al., 2005).

Cytogenetics

Cytogenetics morphological

The t(11;19)(q23;p13.3) was the sole abnormality in the case described by Duhoux et al., 2011, while the cases of Lo Nigro et al., 2002 and Taki et al., 2005 were complex translocations.

Genes involved and proteins

KMT2A (myeloid/lymphoid or mixed lineage leukemia)

Location

11q23.3

DNA/RNA

37 exons, spanning about 120 kb; 13-15 mRNA

Protein

3969 amino acids, 431 kDa; Transcriptional regulatory factor. MLL is known to be associated with more than 30 proteins, including the core components of the SWI/SNF chromatin remodeling

complex and the transcription complex TFIID. MLL binds promoters of HOX genes through acetylation and methylation of histones. MLL is a major regulator of hematopoiesis and embryonic development, through regulation of HOX genes expression regulation (HOXA9 in particular).

MYO1F

Location

19p13.2

DNA/RNA

28 exons, 3297 nucleotides

Protein

1,098 amino acids; 124 KDa; Myosins are a large family of ATP-driven mechanoenzymes. MYO1F belong to myosin class I, which includes myosins that are able to interact with actin filaments and lipid membranes. Presence of three tail homology regions (TH1, TH2 and a SH3 domain named TH3). These "long-tailed" myosins (i.e. with additional TH2 and TH3) are able to crosslink actin filaments via the TH2 domain and generate mechanical activities using the actin cytoskeleton as a tract. MYO1F contains a myosin motor domain (amino acids 17 - 690); this motor domain contains an actin binding site. It has an ATPase activity/cycle with association/dissociation of myosin with actin. The motor domain is followed by an IQ domain (isoleucine/glutamine motifs, aa 693 - 722), and a

TH1 domain (Tail Homology domain, aa 728 - 917). The TH1 domain is responsible for membrane interaction and, within TH1, a pleckstrin homology PH domain which is a negatively charged phospholipids-binding motif. There are several phosphosites located in the TH2 domain, required for binding to microtubules and microfilaments. TH2 is alanine and proline-rich (aa 941 - 1000). The C-terminus is a SH3 domain (SRC Homology 3 domain, aa 1041 - 1098); it should mediate assembly of specific protein complexes via binding to proline-rich peptides. TLR4 activation induces phosphorylation of MYO1F. MYO1F is a cytosolic protein predominantly expressed in the immune system (Wenzel et al., 2015; Walklate et al., 2016).


Result of the chromosomal anomaly

Hybrid gene

Description

KMT2A exon 9 was fused to MYO1F exon 2; the breakpoint was thus located within MLL intron 9 in the cases reported by Taki et al., 2005 and Duhoux et al., 2011. The breakpoint in KMT2A was in intron 10 in cases studied by Meyer et al. 2013.

Fusion protein



KMT2A (MLL) 3969 amino acids

- 1 Ala/Gly/Ser-rich
- 2 Poly-Gly
- 3 AT hooks DNA binding
- 4 poly-Pro
- 5 Zinc finger CXXC-type
- 6 Zinc fingers PHD-type
- 7 Bromo domain
- 8 FYR N-term
- 9 TAD
- 10 FYR C-term
- 11 SET
- 12 post-SET

MYO1F 1098 amino acids (aa)

- 1 Motor (aa 17-690)
 - 2 IQ domain (aa 693-722)
 - 3 TH1: (aa 728-917)
 - 4 TH2 (aa 941-1000)
 - 5 TH3 (SH3) (aa 1041-1098)
- Threonine or serine residues (hydrophilic): S734, S1001, T1005, S1023

t(11;19)(q23;p13) KMT2A/MYO1F

© AtlasGeneticsOncology Jean Loup Huret 2018

KMT2A_MYO1F fusion protein, with AT hooks, zinc fingers CXXC type from KMT2A in N-terminus, fused to the entire MYO1F protein in C-terminus.

infant acute myeloid leukemias. Leuk Res. 2011 Sep;35(9):e171-2

L. Lo Nigro, D.J. Slater, E.F. Rappaport, A. Biondi, S. Maude, M.D. Megonigal, et al.. Two new partner genes of MLL and additional heterogeneity in t(11;19)(q23;p13) translocations Blood, 100 (2002), p. 531a

References

Duhoux FP, Ameye G, Libouton JM, Bahloula K, Iossifidis S, Chantrain CF, Demoulin JB, Poirel HA. The t(11;19)(q23;p13) fusing MLL with MYO1F is recurrent in

Meyer C, Hofmann J, Burmeister T, Groger D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, Cave H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh SH, Tsauro G, Fechina L, van der Velden VH, van Dongen JJ, Delabesse E, Binato R, Silva ML, Kustanovich A, Aleinikova O, Harris MH, Lund-Aho T, Juvonen V, Heidenreich O, Vormoor J, Choi WW, Jarosova M, Kolenova A, Bueno C, Menendez P, Wehner S, Eckert C, Talmant P, Tondeur S, Lippert E, Launay E, Henry C, Ballerini P, Lapillone H, Callanan MB, Cayuela JM, Herbaux C, Cazzaniga G, Kakadiya PM, Bohlander S, Ahlmann M, Choi JR, Gameiro P, Lee DS, Krauter J, Cornillet-Lefebvre P, Te Kronnie G, Schafer BW, Kubetzko S, Alonso CN, zur Stadt U, Sutton R, Venn NC, Izraeli S, Trakhtenbrot L, Madsen HO, Archer P, Hancock J, Cerveira N, Teixeira MR, Lo Nigro L, Moricke A, Stanulla M, Schrappe M, Sedek L, Szczepanski T, Zwaan CM, Coenen EA, van den Heuvel-Eibrink MM, Strehl S, Dworzak M, Panzer-Grumayer R, Dingermann T, Klingebiel T, Marschalek R. The MLL recombinome of acute leukemias in 2013 *Leukemia* 2013 Nov;27(11):2165-76

Taki T, Akiyama M, Saito S, Ono R, Taniwaki M, Kato Y, Yuza Y, Eto Y, Hayashi Y. The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22 *Oncogene* 2005 Aug 4;24(33):5191-7

Walklate J, Ujjalusi Z, Geeves MA.. Myosin isoforms and the mechanochemical cross-bridge cycle. *J Exp Biol.* 2016 Jan;219(Pt 2):168-74. doi: 10.1242/jeb.124594. Review.

Wenzel J, Ouderkirk JL, Krendel M, Lang R.. Class I myosin Myo1e regulates TLR4-triggered macrophage spreading, chemokine release, and antigen presentation via MHC class II. *Eur J Immunol.* 2015 Jan;45(1):225-37. doi: 10.1002/eji.201444698. Epub 2014 Nov 2.

This article should be referenced as such:

Huret JL. t(11;19)(q23;p13) KMT2A/MYO1F. *Atlas Genet Cytogenet Oncol Haematol.* 2018; 22(11):472-474.
